Pfizer to Build $650 Million Manufacturing Technology Center in Groton, Connecticut

Global biopharmaceutical company Pfizer plans to build a Manufacturing Technology Center at its research and development campus in Groton, Connecticut, representing a $650 million capital investment over the next five years, AdvanceCT announced.

Clinical drug production under one roof

The approximately 220,000-square-foot facility will produce clinical active pharmaceutical ingredients and drug products that support Pfizer-sponsored clinical trials around the world. Construction is planned to begin in the second quarter of 2027, with operational startup targeted for mid-2031. The project will consolidate employees currently working in other facilities across the Groton campus into a modern, purpose-built center.

Raja Mangipudy, Ph.D., Groton site head at Pfizer said:

“Pfizer has a long and proud history of scientific innovation in Groton, where many of the discoveries that advance our pipeline begin. Building on that legacy, the new Manufacturing Technology Center will advance our ability to support clinical research and the development of new medicines for patients around the world.”

John Bourdeaux, president and CEO of AdvanceCT said:

“The Manufacturing Technology Center will connect scientific discovery with the advanced manufacturing capabilities needed to support clinical trials around the world. It is a significant vote of confidence in Groton, its workforce, and Connecticut’s ability to support biopharmaceutical innovation at a global scale.”